Lymphoma
Each year, more than 400,000 people worldwide develop tumours of the lymphatic system (lymphoma), and around half that number die from the disease. Better treatments are especially being sought for non-Hodgkin’s lymphoma — the incidence of which is climbing but for which successful treatments are elusive. This Outlook explores research on the origins, diagnosis and treatment of the complex group of cancers that constitutes lymphoma.
This Nature Outlook is editorially independent. It is produced with third party financial support. About this content.
This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge financial support from F. Hoffmann-La Roche in producing this Outlook. The sponsor retains sole responsibility for the following message.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast. The Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies.
For more information on Roche ’s approach to cancer, visit Roche.com.
Read the Roche sponsor feature on: Obinutuzumab for the treatment of non-Hodgkin lymphomas
Read the Roche sponsor feature on: Non-Hodgkin lymphoma: Treatment advances for diffuse large B-cell lymphoma
